Compare TWAV & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWAV | JAGX |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.9M |
| IPO Year | 2000 | 2014 |
| Metric | TWAV | JAGX |
|---|---|---|
| Price | $1.60 | $3.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.7K | ★ 3.1M |
| Earning Date | 11-12-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.77 | 82.42 |
| EPS | ★ 0.43 | N/A |
| Revenue | $2,437,000.00 | ★ $11,511,000.00 |
| Revenue This Year | N/A | $77.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | ★ 2.48 | N/A |
| 52 Week Low | $0.58 | $0.20 |
| 52 Week High | $2.58 | $41.53 |
| Indicator | TWAV | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 61.98 | 49.80 |
| Support Level | $1.14 | $0.89 |
| Resistance Level | $1.75 | $8.00 |
| Average True Range (ATR) | 0.13 | 4.48 |
| MACD | 0.02 | -0.30 |
| Stochastic Oscillator | 82.35 | 10.26 |
TaoWeave Inc is a digital asset company. The company offers investors a regulated, publicly traded vehicle to gain exposure to the decentralized AI economy. The company aims to invest in the Bittensor ecosystem through partnerships with subnets, miners, and validators, and operates with zero debt by maintain appropriate cash reserves. The Company currently operates in three segments: (1) "Digital Assets", which represents the business surrounding treasury activity with Bittensor, (2) Collaboration Products which represents the business surrounding Mezzanine product offerings, and (3) Managed Services, which represents the business surrounding managed services for video collaboration and network solutions.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.